# A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.

> **NCT06130007** · PHASE2 · UNKNOWN · sponsor: **Xuekui Liu** · enrollment: 48 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy

## Key facts

- **NCT ID:** NCT06130007
- **Lead sponsor:** Xuekui Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-25
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06130007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06130007, "A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06130007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*